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Objective in patients indicated for cardiac resynchronisation therapy (crt), the choice between a crt-pacemaker (crt-P) versus defibrillator (crt-D) remains controversial and indications in this setting have not been well delineated. apart from inappropriate therapies, which are inherent to the presence of a defibrillator, whether adding defibrillator to crt in the primary prevention setting impacts risk of other acute and late device-related complications has not been well studied and may bear relevance for device selection. Methods Observational multicentre european cohort study of 3008 consecutive patients with ischaemic or non-ischaemic dilated cardiomyopathy and no history of sustained ventricular arrhythmias, undergoing crt implantation with (crt-D, n=1785) or without (crt-P, n=1223) defibrillator. Using propensity score and competing risk analyses, we assessed the risk of significant device-related complications requiring surgical reintervention. inappropriate shocks were not considered except those due to lead malfunction requiring lead revision. results acute complications occurred in 148 patients (4.9%), without significant difference between groups, even after considering potential confounders (Or=1.20, 95% ci 0.72 to 2.00, p=0.47). During a mean follow-up of 41.4±29 months, late complications occurred in 475 patients, giving an annual incidence rate of 26 (95% ci 9 to 43) and 15 (95% ci 6 to 24) per 1000 patient-years in crt-D and crt-P patients, respectively. crt-D was independently associated with increased occurrence of late complications (hr=1.68, 95% ci 1.27 to 2.23, p=0.001). in particular, when compared with crt-P, crt-D was associated with an increased risk of device-related infection (hr 2.10, 95% ci 1.18 to 3.45, p=0.004). acute complications did not predict overall late complications, but predicted device-related infection (hr 2.85, 95% ci 1.71 to 4.56, p<0.001).
Conclusions compared with crt-P, crt-D is associated with a similar risk of periprocedural complications but increased risk of long-term complications, mainly infection. this needs to be considered in the decision of implanting crt with or without a defibrillator.
InTrOduCTIOn
Cardiac resynchronisation therapy (CRT) is associated with improved survival in patients with heart failure with ischaemic or non-ischaemic dilated cardiomyopathy (DCM), prolonged QRS duration and severe left ventricular (LV) systolic dysfunction. 1 Current guidelines recommend an implantable cardioverter-defibrillator (ICD) for the prevention of sudden cardiac death (SCD) in symptomatic patients with an LV ejection fraction of ≤35% 2 and thus most patients undergoing CRT get a CRT-defibrillator (CRT-D). However, the magnitude of incremental benefit of the primary prevention defibrillator in this setting is a matter of some debate. Furthermore, the addition of a defibrillator lead and the bulkier device may potentially increase the risk of device-related complications. Previous investigators have assessed the acute and short-term to mid-term risk of device-related complications among large cohorts of ICD and CRT-D patients. 3 4 Nevertheless, except for few studies involving limited number of CRT-pacemaker (CRT-P) patients followed for a relatively short duration, 5-7 there has not been any large study comparing CRT-D with CRT-P regarding the acute and late risk of device-related complication.
Although inappropriate therapies as a complication would obviously be restricted to the CRT-D population, this can be reasonably assessed only in the context of potential lives saved by appropriate therapies or any mortality reduction vis-à-vis CRT-D versus CRT-P, which is the subject matter of a separate ongoing debate. 8 9 However, whether other complications differ significantly between CRT-D versus CRT-P has not been well studied in adequate numbers of patients and is an important issue to consider in decision-making. In this large observational multicentre study, we aimed to compare the outcome of CRT-D versus CRT-P patients with respect to the risk of acute and late device-related complications.
MeTHOds study design and setting
Data were obtained from a large European consortium totalling 3008 patients with ischaemic or Heart failure and cardiomyopathies non-ischaemic DCM without history of sustained ventricular arrhythmia receiving CRT-D or CRT-P between 2006 and 2013. [9] [10] [11] Indications were as per the European Society of Cardiology and European Heart Rhythm Association guidelines 12 for patients treated in France and the National Institute for Health and Care Excellence guidelines (https://www. nice. org. uk/ guidance/ ta120) for British patients.
Using proportional hazards regression and propensity score analysis, 13 14 we compared the outcome of CRT-D versus CRT-P patients with regard to acute and late risk of device-related complications, taking the competing risk of death into consideration.
The CeRtiTuDe cohort study protocol was approved by the French Ethics and Data Protection National Committees. Data analysis in the remaining Hospitals was approved by the individual sites' institutional review boards.
Patient eligibility criteria and sample characterisation
Of the 3008 patients, 1785 (59.3%) received a CRT-D while the remaining 1223 (40.7%) received a CRT-P. All procedures were new implants or upgrades from a standard pacemaker. Patients with a cardiomyopathy other than ischaemic or non-ischaemic DCM or a previous history of sustained ventricular arrhythmia were not included. Data collected: demographics, aetiology, renal dysfunction (glomerular filtration rate <30 mL/min), atrial fibrillation (AF), chronic obstructive pulmonary disease, cerebrovascular event, diabetes mellitus, cancer, type of device, de novo implantation versus upgrade, LV function, New York Heart Association (NYHA) class and medication including betablocker, angiotensin-converting enzyme inhibitor or angiotensin II receptor blockers, aldosterone antagonists, antiplatelet and anticoagulant drugs. Device programming was left to the discretion of the investigators at each centre, with the guiding principle being achievement of maximal biventricular pacing.
study endpoints and follow-up
The primary endpoint of the study was the occurrence of a complication related to the implanting procedure or the device itself which required surgical reintervention. Complications were divided into (1) acute, defined as a complication occurring during the implanting procedure or diagnosed prior to hospital discharge and (2) late, defined as a complication occurring or diagnosed following hospital discharge and which had not been seen to occur during the index hospitalisation. Complications which were managed conservatively and did not require surgical intervention were not included in our analysis, except for pocket haematoma requiring transfusion and venous thrombosis requiring anticoagulation. Inappropriate shocks, which can occur only in the CRT-D group, were not considered except when it was due to lead malfunction requiring lead revision. This was done for the reasons outlined in the introduction earlier; essentially we did an unbiased comparison of those complications which would have a possibility to occur in either group. Complications were further classified into four categories:
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► Access-related: Any complication which occurred while gaining access to the vasculature or which was vessel-related, including (1) pneumothorax or haemothorax requiring chest drain insertion or surgery and (2) venous thrombosis and/or occlusion requiring anticoagulation. ► Lead-related: Any complication related directly to the positioning of the lead or the lead itself requiring lead replacement or repositioning, including (1) lead dysfunction (due to fracture or insulation defect), (2) lead displacement, (3) phrenic nerve stimulation without macro lead displacement, (4) loose set screw; (5) coronary sinus dissection causing cardiac tamponade and/or preventing completion of the implant and (6) lead perforation. ► Generator-related: Any complication other than infection related directly to the generator itself or its pocket, including (1) premature device failure requiring generator replacement, (2) pocket haematoma requiring surgical drainage and/or blood transfusion, (3) chronic pain or threatened erosion requiring pocket revision. ► Infection: Any device-related infection requiring surgical intervention, either extraction or pocket/wound revision, but not causing the death of the patient. ► Device-related death: Any death directly caused by a device-related complication (such as systemic infection) or complication during the implanting procedure or when these were considered to have contributed to the death of the patient. This subgroup included all cases of periprocedural death, defined as death during the same hospital admission. When definite data on the type of complication were unavailable, these were labelled as 'unclassified'.
Patients were followed at 6-month intervals. Additional unscheduled visits or remote ICD interrogations were performed in CRT-D patients receiving ICD shocks. The investigators at each centre recorded major clinical events and the accuracy of the data was verified, on an yearly basis, by crosschecking of clinical notes from hospital admissions, procedural reports, information provided by treating physicians and electronic medical records, focusing on the vital status, specific modes/ causes of death, major clinical events, interventions as well as interim hospitalisations during follow-up.
statistical analysis
Statistical analysis was performed using IBM SPSS Statistics, V.24. Baseline characteristics were described with mean±SD deviation for continuous data and counts and proportions for categorical data. The Kolmogorov-Smirnov test was used to test the normal distribution of continuous variables. The χ² test, Student's t-test and non-parametric equivalent tests were used when appropriate. P<0.05 (two-sided) were considered statistically significant. Missing data were assumed to be random and were treated with multiple imputation by chained equations. However, the results of an analysis restricted to complete cases are also presented.
The outcome of CRT-D versus CRT-P patients with regard to the occurrence of (1) any acute complication, (2) any late complication and (3) infection was compared using logistic regression (for acute complications) or proportional hazards regression (for late complications) with adjustment on the propensity score and all predictors of complications in univariate analysis. The time to complication was of primary interest, but the occurrence of death (the competing event) would preclude its occurrence. Therefore, we calculated yearly cause-specific incidence rates using the method described by Wolbers et al 16 and performed competing risk regression using the Fine-Gray model for obtaining subdistribution hazard ratios (sHR). Similar analysis was performed for the endpoint infection, as death would also be a competing event.
The analysis was complemented with propensity score matching. Greedy nearest-neighbour matching within a specified calliper width (0.01), without replacement, was used for forming pairs of CRT-D and CRT-P patients matched on the propensity score. 17 In order to assess the balance on the newly created propensity score (PS)-matched sample, we compared standardised differences in the means of continuous and binary covariates between treatment groups.
13 After the matched sample was created, comparison between device groups was performed taking into account the matched nature of the data (logistic regression estimated using a generalised estimating equation for acute complications and Cox regression stratified on matched pairs for late complications). The proportional hazards assumption was tested with time by covariate interaction. For obtaining the propensity score, we included all baseline covariates that were shown to associate with the occurrence of complications or the competing risk of mortality. 18 Assuming a 10.5% 3-year rate of 'unanticipated events' requiring system revision among CRT-D patients, 3 and 6-month risk of major complications of 11% for CRT-D patients and 6.7% for those receiving CRT-P, 5 we estimated that a sample size of 2374 patients (1187 per group) followed for approximately 3 years would provide 95% power to detect a similar difference in complication risk at a two-tailed alpha level of 0.05.
resulTs study population
Baseline characteristics of the entire population are reported in table 1. CRT-P patients were older, more often female and had more advanced heart failure and comorbidity. Ischaemic cardiomyopathy was more frequent in CRT-D patients, and they were more often treated with standard heart failure medi- While acute complication data were obtained for the whole study group, data on late complications were available for 2754 patients (91.6%) of the cohort, without significant difference between the two groups.
Acute complications
Overall, acute complication occurred in 148 patients (4.9%). Lead displacement was the most frequent acute complication (n=43, 1.4%), followed by pocket haematoma (n=23, 0.8%) and pneumothorax (n=20, 0.7%). Acute complications occurred in 88 CRT-D (4.9%) and 60 CRT-P patients (4.9%), with a similar pattern with respect to the details of complications (table 2) . Implantation of a CRT-D device was not associated with an increased risk of acute complications (OR=1.16, 95% CI 0.71 to 1.89, p=0.56) when adjusted for age, sex, aetiology, upgrade versus de novo implantation and the propensity score. After multivariate adjustment and multiple imputation for missing data, the type of device was not associated with occurrence of acute complications (OR=1.2, 95% CI 0.72 to 2.0, p=0.47). In addition, after propensity-score matching (n=1404; 702 per group) and after confirming that groups were well balanced (online supplementary table 1), the risk of acute complications 
late complications
Late complications were reported in 285 patients (10.4%). Device-related infection (n=79) was the most frequent, followed by lead displacement (n=76) and lead dysfunction (n=73). The mean annual cause-specific incidence rate of late complications was 26 (95% CI 9 to 43) and 15 (95% CI 6 to 24) per 1000 patient-years in CRT-D and CRT-P patients respectively. Figure 1 illustrates annual cause-specific incidence rates of complications in both device groups, while 
0%).
The mean annual cause-specific incidence of infection was 9 (95% CI 3 to 14) and 5 (95% CI 1 to 9) per 1000 patientyears in CRT-D and CRT-P patients, respectively. After considering potential confounders, CRT-D was significantly associated with device-related infection compared with CRT-P (4.3% vs 2.7%; sHR=2.1, 95% CI 1.18 to 3.45, p=0.004). Other factors associated with late infection included upgrade to CRT (sHR=2.46±0.21, p<0.001) and the occurrence of a previous acute complication (sHR=2.85±0.28, p<0.001). Figure 3 illustrates the cumulative risk of infection over time when considering the competing risk of mortality. In the propensity score-matched cohort, infection was more frequent in CRT-D patients (4.9% vs 2.3%; sHR=2.58, 95% CI 1.36 to 5.1, p=0.009). Infection occurred during the first 12 months of follow-up in 56.7% of cases. Patients younger than 65 years and receiving upgrade to CRT-D were at particularly high risk of infection (10.7%).
Without imputed data, CRT-D implantation remained associated with an increased risk of late complications (sHR=1.61, Figure 1 Forest plots illustrating cause-specific incidence rate of follow-up complications and device-related infections in both device groups. CRT, cardiac resynchronisation therapy; CRT-D, CRT-defibrillator; CRT-P, CRT-pacemaker. 95% CI 1.14 to 2.31, p=0.001) when adjusted for age, sex, aetiology, upgrade versus de novo implantation, the propensity score and the occurrence of an acute complication at time of implantation and an increased infection risk, (sHR=1.9, 95% CI 1.25 to 3.52, p=0.002). Online supplementary table 2 compares CRT-D versus CRT-P patients with respect to frequently recognised risk factors for infection.
dIsCussIOn
Our findings suggest that the addition of the defibrillator in patients receiving CRT associates with a higher risk of device-related complications compared with CRT alone. The difference is mostly accounted for by an increase in the risk of late complications, in particular infection, while the risk of acute complications is similar.
The indications for the ICD and CRT often overlap. However, there has never been any randomised trial specifically comparing CRT-D versus CRT-P in patients with heart failure. Recent registry and observational data suggest that CRT alone may still be appropriate in the primary prevention setting in specific groups of patients, 8 9 but this is an area of ongoing debate. 6 8 9 19-21 Studies have strongly suggested that additional ICD likely reduces mortality in men and in ischaemic cardiomyopathy, 8 while in other subgroups such as the elderly, women and patients with non-ischaemic DCM, the evidence for a putative additional benefit over and above CRT appears questionable. 22 In these patients, the risk/benefit ratio may also depend on whether the addition of the ICD associates with increased risk of device-related comorbidity and complications.
Although several studies have assessed the risk of complications in patients receiving ICD or CRT-D, 3 4 23 no large study has thus far compared the outcome of CRT-D versus CRT-P with regard to the adjusted risk of device-related complications. It is known that CRT-D devices are associated with a higher risk of shortterm and long-term device-related events than single-chamber or dual-chamber ICDs. 3 23 A previous study revealed an increased risk of complications in patients receiving dual-chamber ICD or CRT-D compared with pacemakers or CRT-P. 5 However, this study included a small number of CRT-P patients followed for 6 months only. An additional small study observed a nearly threefold higher 12-month risk of lead dysfunction in CRT-D compared with CRT-P patients, while the rate of system-related infections was similar in both groups. 6 In the European CRT survey, the unadjusted risk of perioperative complications was not significantly different between CRT-D and CRT-P patients.
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To the best of our knowledge, we provide the first assessment and comparison of both acute and late complications among patients receiving CRT-D versus CRT-P taking into account the competing risk of death as well as the well-recognised treatment selection bias by performing propensity score analysis. We observed that perioperative complications occur similarly in both device groups, as seen in the European CRT survey, 24 and the increased follow-up complication risk among CRT-D patients is accounted for by a greater incidence of lead-related and generator-related complications and, quite importantly, infection. The increased risk of overall complications in CRT-D recipients is possibly explained by the increased device/lead complexity.
However, the increased risk of infection has not been well acknowledged before. An unadjusted analysis by Sohail et al reported a similar infection rate between those receiving CRT-D and CRT-P, 25 while Unsworth and colleagues reported that late infection rate in patients with cardiac electronic devices is mostly driven by increased CRT-D infection. 26 It seems plausible that CRT-D patients may be at increased risk of infection. Compared with CRT-P recipients, those receiving CRT-D are more likely to Heart failure and cardiomyopathies require anticipated generator replacement due to shorter battery life and unanticipated reintervention due to lead dysfunction and wound issues, as we have shown. Surgical reintervention is undoubtedly one of the most important predictors of infection among cardiac electronic device recipients. 27 In our study, the occurrence of a previous acute complication requiring surgical intervention predicted a higher risk of infection, as expected. Also, CRT-D patients have a higher mean number of leads given their lower incidence of AF and the fact that patients having upgrade from pacemaker to CRT-D receive two new leads, while upgrade to CRT-P requires one new lead only. The extra number of leads in CRT-D patients may have also contributed to the increased infection risk. Furthermore, CRT-D recipients are more often men and younger compared with CRT-P patients. These factors have been shown to associate with an increased risk of infection. 28 However, the higher infection risk amid CRT-D recipients in our study was seen to be independent of sex and age. In patients at lower risk of SCD, the addition of the ICD should be carefully weighed, as the lower complication risk of a biventricular pacemaker may outweigh the small benefit of the ICD in a low-SCD risk setting. Device-related infection may result in a substantial increase in both hospital admissions and long-term mortality. 25 The future development of smaller devices with thinner leads to reduce pocket bulk and longer battery-lives thus reducing the need for reintervention may have a favourable impact on the CRT-D risk-benefit ratio. Also, a lower threshold for subpectoral implants and antibacterial envelope usage may be justifiable among CRT-D recipients.
limitations of this study
The non-randomised nature of this study is its main limitation. Propensity score analysis can only account for measured variables. In particular, the absence of data regarding operator and centre experience should be considered when interpreting our results. It is possible that late complications may be less frequent in centres with greater experience with device follow-up; however, all centres involved in this study were high volume, academic centres and centre-specific differences would not be expected to be large. Inappropriate shocks which did not result in surgical reintervention were not considered in this study, as we aimed to compare complications common to both CRT-D and CRT-P patients. However, inappropriate shocks may represent additional morbidity and distress among CRT-D patients. In our study, inappropriate shocks were reported in 4.9% of patients receiving CRT-D.
Data on late complications were not available for 8.7% of patients. However, this group was not significantly different from the remaining 91.3% with complete data. This suggests that missing data occurred at random and would be unlikely to significant influence the main findings of our study.
COnClusIOn
In patients receiving CRT, the addition of an ICD is associated with an increased risk of complications during follow-up, particularly infection. Treating physicians should factor in the potential added risk of complications into their discussion with the patient and the decision-making process. 
